Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study
- PMID: 33778792
- PMCID: PMC7987301
- DOI: 10.1016/S2666-5247(21)00025-2
Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study
Erratum in
-
Correction to Lancet Microbe 2021; published online March 23. https://doi.org/10.1016/S2666-5247(21)00025-2.Lancet Microbe. 2021 May;2(5):e179. doi: 10.1016/S2666-5247(21)00088-4. Epub 2021 Apr 9. Lancet Microbe. 2021. PMID: 33870239 Free PMC article.
Abstract
Background: Studies have found different waning rates of neutralising antibodies compared with binding antibodies against SARS-CoV-2. The impact of neutralising antibody waning rate at the individual patient level on the longevity of immunity remains unknown. We aimed to investigate the peak levels and dynamics of neutralising antibody waning and IgG avidity maturation over time, and correlate this with clinical parameters, cytokines, and T-cell responses.
Methods: We did a longitudinal study of patients who had recovered from COVID-19 up to day 180 post-symptom onset by monitoring changes in neutralising antibody levels using a previously validated surrogate virus neutralisation test. Changes in antibody avidities and other immune markers at different convalescent stages were determined and correlated with clinical features. Using a machine learning algorithm, temporal change in neutralising antibody levels was classified into five groups and used to predict the longevity of neutralising antibody-mediated immunity.
Findings: We approached 517 patients for participation in the study, of whom 288 consented for outpatient follow-up and collection of serial blood samples. 164 patients were followed up and had adequate blood samples collected for analysis, with a total of 546 serum samples collected, including 128 blood samples taken up to 180 days post-symptom onset. We identified five distinctive patterns of neutralising antibody dynamics as follows: negative, individuals who did not, at our intervals of sampling, develop neutralising antibodies at the 30% inhibition level (19 [12%] of 164 patients); rapid waning, individuals who had varying levels of neutralising antibodies from around 20 days after symptom onset, but seroreverted in less than 180 days (44 [27%] of 164 patients); slow waning, individuals who remained neutralising antibody-positive at 180 days post-symptom onset (46 [28%] of 164 patients); persistent, although with varying peak neutralising antibody levels, these individuals had minimal neutralising antibody decay (52 [32%] of 164 patients); and delayed response, a small group that showed an unexpected increase of neutralising antibodies during late convalescence (at 90 or 180 days after symptom onset; three [2%] of 164 patients). Persistence of neutralising antibodies was associated with disease severity and sustained level of pro-inflammatory cytokines, chemokines, and growth factors. By contrast, T-cell responses were similar among the different neutralising antibody dynamics groups. On the basis of the different decay dynamics, we established a prediction algorithm that revealed a wide range of neutralising antibody longevity, varying from around 40 days to many decades.
Interpretation: Neutralising antibody response dynamics in patients who have recovered from COVID-19 vary greatly, and prediction of immune longevity can only be accurately determined at the individual level. Our findings emphasise the importance of public health and social measures in the ongoing pandemic outbreak response, and might have implications for longevity of immunity after vaccination.
Funding: National Medical Research Council, Biomedical Research Council, and A*STAR, Singapore.
© 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7987301/bin/gr1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7987301/bin/gr2.gif)
Similar articles
-
Direct enhancement of viral neutralising antibody potency by the complement system: a largely forgotten phenomenon.Cell Mol Life Sci. 2024 Jan 11;81(1):22. doi: 10.1007/s00018-023-05074-2. Cell Mol Life Sci. 2024. PMID: 38200235 Free PMC article. Review.
-
SARS-CoV-2 neutralising antibody therapies: Recent advances and future challenges.Rev Med Virol. 2023 Sep;33(5):e2464. doi: 10.1002/rmv.2464. Epub 2023 Jun 15. Rev Med Virol. 2023. PMID: 37322826 Review.
-
SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.Lancet Microbe. 2022 May;3(5):e348-e356. doi: 10.1016/S2666-5247(22)00036-2. Epub 2022 Mar 23. Lancet Microbe. 2022. PMID: 35345417 Free PMC article.
-
Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19.EBioMedicine. 2021 Sep;71:103519. doi: 10.1016/j.ebiom.2021.103519. Epub 2021 Aug 19. EBioMedicine. 2021. PMID: 34419923 Free PMC article.
-
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.Lancet Respir Med. 2021 Sep;9(9):999-1009. doi: 10.1016/S2213-2600(21)00220-4. Epub 2021 Jul 2. Lancet Respir Med. 2021. PMID: 34224675 Free PMC article.
Cited by
-
Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children.Nat Med. 2024 May;30(5):1373-1383. doi: 10.1038/s41591-024-02962-3. Epub 2024 Apr 30. Nat Med. 2024. PMID: 38689059 Free PMC article.
-
Validation and Suitability Assessment of Multiplex Mesoscale Discovery Immunogenicity Assay for Establishing Serological Signatures Using Vaccinated, Non-Vaccinated and Breakthrough SARS-CoV-2 Infected Cases.Vaccines (Basel). 2024 Apr 18;12(4):433. doi: 10.3390/vaccines12040433. Vaccines (Basel). 2024. PMID: 38675815 Free PMC article.
-
Immunogenicity Assessment of the SARS-CoV-2 Protein Subunit Recombinant Vaccine (CoV2-IB 0322) in a Substudy of a Phase 3 Trial in Indonesia.Vaccines (Basel). 2024 Apr 1;12(4):371. doi: 10.3390/vaccines12040371. Vaccines (Basel). 2024. PMID: 38675753 Free PMC article.
-
The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role.Oxf Open Immunol. 2021 Feb 23;2(1):iqab006. doi: 10.1093/oxfimm/iqab006. eCollection 2021. Oxf Open Immunol. 2021. PMID: 38626271 Free PMC article. Review.
-
Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination.Nat Immunol. 2024 Apr;25(4):633-643. doi: 10.1038/s41590-024-01787-z. Epub 2024 Mar 14. Nat Immunol. 2024. PMID: 38486021 Free PMC article.
References
-
- WHO COVID-19 situation reports. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situatio...
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous